Zortress (Everolimus) Patent Expiration, LOE Window & CMS Spending

Zortress (Everolimus) by Novartis: Off-Patent Genericized (AB Competition), 13 AB generics, $3.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN021560 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$3.0M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$1.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.